Patented specialized probiotics
Free Shipping on All Orders Above SGD100
100% Natural and Safe
Patented specialized probiotics
Scientifically backed formula
100% Natural and Safe
Vicofem® Clinical Studies: Women’s Health Support

Vicofem® Clinical Studies: Women’s Health Support

in Clinical Studies

Main Finding: Vicofem® supports women’s health by reducing BV recurrence, protecting against urogenital pathogens, and improving vaginal health in post‑menopause.

Better gut, Better Health, Better You

Study 1

Reducing Recurrence of Bacterial Vaginosis

Objective

To test whether oral supplementation with SynbÆctive® Femme reduces recurrence of bacterial vaginosis (BV, an imbalance of vaginal microbiota) after antibiotic treatment.

Methodology

Women with BV received metronidazole; 50 additionally took SynbÆctive® Femme daily for 5 months, while 25 served as control.

Results

BV recurrence was 16% in the probiotic group vs. 40% in controls. Vaginal microbiota showed greater normalization in the probiotic group.

Conclusion

Vicofem® significantly reduces BV recurrence and helps restore healthy vaginal microbiota.

Results:

Study Result Image

Murina, F., & Vicariotto, F. (2019). Evaluation of an orally administered multistrain probiotic supplement in reducing recurrences rate of bacterial vaginosis: A clinical and microbiological study. Advances in Infectious Diseases, 9(3), 151–161.

Study 2

Antimicrobial & Barrier Protection (In Vitro)

Objective

To evaluate the antimicrobial, anti‑adhesive, and co‑aggregation activity of SynbÆctive® Femme against urogenital pathogens.

Methodology

In vitro (lab‑based, outside the body) tests on reconstructed human vaginal and bladder epithelium (protective cell lining) infected with Candida glabrata, Neisseria gonorrhoeae, Trichomonas vaginalis, and Escherichia coli.

Results

The probiotic blend completely inhibited Trichomonas vaginalis, strongly reduced Candida glabrata and Neisseria gonorrhoeae, and blocked Escherichia coli adhesion while preserving epithelial integrity.

Conclusion

Vicofem® protects against multiple pathogens and supports vaginal barrier health.

Results:

Study Result Image

Malfa, P., Brambilla, L., Giardina, S., Masciarelli, M., Squarzanti, D. F., Carlomagno, F., & Meloni, M. (2023). Evaluation of antimicrobial, antiadhesive and co‑aggregation activity of a multi‑strain probiotic composition against different urogenital pathogens. International Journal of Molecular Sciences, 24(2), 1323.

Study 3

Improving Vaginal Health in Post‑Menopausal Women

Objective

To assess the effect of SynbÆctive® Femme on vaginal health outcomes in post‑menopausal women.

Methodology

Post‑menopausal women supplemented daily for 28 days. Outcomes measured: vaginal pH (acidity level; a healthy vagina is slightly acidic), Vaginal Health Index (VHI, a score of elasticity, moisture, and mucosa integrity), and Lactobacillus abundance.

Results

Vaginal pH improved towards a healthy acidic range; VHI scores increased (better elasticity, secretion, and mucosa integrity); Lactobacillus levels rose significantly.

Conclusion

Vicofem® restores a Lactobacillus‑dominated microbiota and enhances vaginal well‑being in menopause.

Results:

Study Result Image

Vicariotto, F., Malfa, P., Viciani, E., Dell’Atti, F., Squarzanti, D. F., Marcante, A., Castagnetti, A., Ponchia, R., Governini, L., & De Leo, V. (2024). Efficacy of Lactiplantibacillus plantarum PBS067, Bifidobacterium animalis subsp. lactis BL050, and Lacticaseibacillus rhamnosus LRH020 in the amelioration of vaginal microbiota in post-menopausal women: A prospective observational clinical trial. Nutrients, 16(3), 402.

Home Search Cart Products